Physician profile
Claude Louis
NPI 1427311091
$2,439.55
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $50.21 · 2021: $197 · 2022: $32.95 · 2023: $282 · 2024: $413 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $440.55 | 2019 | |
| Pfizer INC. | $242.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.39 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $186.13 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $175.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $151.93 | 2023-2025 | Freestyle Libre 3, Mitraclip |
| Amgen INC. | $151.80 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.86 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $123.56 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $114.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $79.70 | 2019-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $75.37 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $60.38 | 2019-2023 | Camzyos |
| Biohaven Pharmaceuticals, INC. | $42.97 | 2021 | |
| Dexcom, INC. | $39.82 | 2023-2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.19 | 2024-2025 | |
| Exact Sciences Corporation | $36.84 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $29.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $27.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.62 | 2024 | Xifaxan |
| Redhill Biopharma INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.